… Former smokers had a greater risk of disease development (HR 1.48; 95% CI 1.32 to 1.66).
Use of mirtazapine (HR 0.34; 95% CI 0.15 to 0.77), SNRI (HR 0.46; 95% CI 0.25 to 0.83), …

… Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative
colitis (UC), has emerged as a global disease with high incidence, long duration, devastating …

… diseases that are multifactorial in origin and are usually categorized clinically into Crohn’s
disease (CD), ulcerative colitis … chronic intestinal inflammation are thought to develop primarily …

… disease are at the risk of developing strictures; while in UC, patients with extensive colitis
and long-standing disease … who are experienced in inflammatory bowel disease (IBD) should …

… Inflammatory bowel disease (IBD), as a global disease, has attracted much research interest.
Constant research has led to a better understanding of the disease … patients may develop …

… The scenario is different in developing countries where biologics are used only in a small …
However, approximately one-third of patients are intolerant or develop adverse effects with …

… individuals with Crohn’s disease (CD) or ulcerative colitis (UC). Thus, little is known about
the safety and the efficacy of these vaccines in patients with inflammatory bowel disease (IBD), …

Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by
gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition …

… Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing inflammatory
diseases of … facilitated therapeutic development. UC and CD display heterogeneity in …

… A recent meta-analysis found an overall increased risk of Parkinson’s disease development
compared to control individuals (risk ratio (RR): 1.41; 95% CI: 1.19 - 1.66). Patients with CD …